Navigation Links
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Date:12/12/2011

management for unexpected weight gain. The probability of edema tended to be increased among older patients (>65 years) or those taking higher doses of GLEEVEC. If severe fluid retention occurs, GLEEVEC should be withheld until the event has resolved and then resumed depending on the initial severity of the event.

Cytopenias have been reported. Complete blood counts should be performed weekly for the first month, biweekly for the second month, and periodically thereafter as clinically indicated (for example, every 2-3 months). Dose reduction or treatment interruption may be required for severe neutropenia or thrombocytopenia (see full Prescribing Information for dose adjustment recommendations).

Severe congestive heart failure and left ventricular dysfunction have occasionally been reported. Most patients with reported cardiac events have had other comorbidities and risk factors, including advanced age and previous medical history of cardiac disease. Patients with cardiac disease or risk factors for cardiac failure should be monitored carefully, and any patient with signs or symptoms consistent with cardiac failure should be evaluated and treated.

Hepatotoxicity, occasionally severe, may occur. Cases of fatal liver failure and severe liver injury requiring liver transplants have been reported with both short-term and long-term use of GLEEVEC. Assess liver function before initiation of treatment and monthly thereafter or as clinically indicated. Monitor liver function when combined with chemotherapy known to be associated with liver dysfunction. A 25% decrease in the recommended dose should be used for patients with severe hepatic impairment. If severe hepatotoxicity occurs, GLEEVEC should be withheld until the event has resolved and then resumed depending on the initial severity of the event.

In the newly diagnosed CML trial, 1.8% of patients had (NCI Grades 3/4) hemorrhage. 

In patients with hypereosinophilic syndrome and
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Acsis Inc., the market leader ... announced today that John DiPalo , Acsis, Chief ... & Demand Chain Executive 2015 Provider Pro to ... leading initiatives to help prepare their companies, and customers, ... climate. This year,s list of Provider Pros to Know ...
(Date:2/27/2015)... , Feb. 27, 2015 Securities lawyers at ... of Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP ) ... share. Concerned SLXP investors are encouraged to contact attorney ... The investigation focuses upon the shareholder value of ... shareholders would receive only $158.00 per share in cash. ...
(Date:2/27/2015)... -- An aggressive campaign to reduce the unnecessary use ... with a dangerous drug-resistant bacteria at The Valley Hospital ... C.diff, is a bacterium that can cause symptoms ranging ... recent article in the New England Journal of Medicine ... the United States " asserts that "C. difficile ...
Breaking Medicine Technology:Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3
... CHAMPION ( C ardioMEMS H eart Sensor A llows M ... N YHA Class III Patients) trial met its primary efficacy endpoint with ... heart failure patients whose treatment was guided by pulmonary artery pressures obtained through ... , The ...
... NEW YORK , June 1 Reportlinker.com announces that a ... , , ... to 2016 - Strategies to Counter Generic Erosion in Key Markets , ... http://www.reportlinker.com/p0203319/The-Future-of-Ophthalmology-Therapeutics-Analysis-and-Market-Forecasts-to-2016---Strategies-to-Counter-Generic-Erosion-in-Key-Markets.html , ...
Cached Medicine Technology:CardioMEMS Completes CHAMPION Clinical Trial Study 2CardioMEMS Completes CHAMPION Clinical Trial Study 3CardioMEMS Completes CHAMPION Clinical Trial Study 4Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 2Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 3Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 4Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 5Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 6Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 7Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 8Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 9Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 10Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 11Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 12Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 13Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 14Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 15Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 16Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 17Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 18Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 19Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 20Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 21Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 22Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 23Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 24Reportlinker Adds The Future of Ophthalmology Therapeutics, Analysis and Market Forecasts to 2016 - Strategies to Counter Generic Erosion in Key Markets 25
(Date:2/28/2015)... February 28, 2015 The MCA Youth ... Malaysia into one platform and gears towards the goal ... A series of group talks in smaller groups will ... Building, Education, Personal Development, Leadership, Entrepreneurship, Healthcare, Social and ... awareness of Malaysian youths. , Young adults ...
(Date:2/28/2015)... Gerald “Solutionman” Haman surveyed over 10,000 ... to innovative thinking. “The #1 block was lack ... tools,” reports Haman, who created the Thinkubator Innovation Studio ... felt that they did not have enough time for ... to stimulate innovation. , Solutionman’s monthly “Accelerating Innovation Training” ...
(Date:2/28/2015)... 2015 March—also known as National ... remind ourselves and others that suspected head injuries, ... Specialists (ANS). , Concussions are a form of ... of TBIs. There are 1.6-3.8 million sports-related concussions ... but it is a brain injury. Many athletes ...
(Date:2/28/2015)... A study out of the University of ... for the treatment of a hereditary ocular condition that ... by Dr. Robert MacLaren, professor of ophthalmology at the ... Journal on January 16, 2014 , the study treated ... that mostly affects men and leads to the degeneration ...
(Date:2/28/2015)... MO (PRWEB) February 28, 2015 ... provider of outsourced sales, marketing and supply chain ... client, BIOTA Botanicals, is bringing its award winning ... worldwide, BIOTA Botanicals’ products are specifically created to ... care experts, BIOTA is committed to marrying science ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 2Health News:New Survey Reveals “Lack of Time” Is the Number #1 Barrier to Innovative Thinking 3Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 2Health News:Atlantic NeuroSurgical Specialists (ANS) Focus on National Brain Injury Awareness Month to Educate the General Public on Head Trauma 3Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 2Health News:BIOTA Botanicals Brings Thinning-Damaged Hair Solutions to the Hair Care Aisle at Walgreens 3
... R.I. [Brown University] Despite evidence that feeding tubes ... for elderly patients with advanced dementia, their frequency of ... of family members finds that discussions surrounding the decision ... Advanced dementia is a terminal illness that often affects ...
... People with dementia may soon have improved oral hygiene ... four-year grant to Rita A. Jablonski, assistant professor of ... disease have all been linked to poor oral hygiene. ... for because they often are no longer able to ...
... of disease progression and response to chemotherapy in breast ... patients, but do not always agree in their predictions ... In recent years, several genomic tests have ... Dr Catherine Kelly from Mater Misericordiae University Hospital, Dublin, ...
... In a rare and medically remarkable operation, a multi-disciplinary team ... Arthur G. James Cancer Hospital and Richard J. Solove ... and pelvis of a cancer patient, and used the healthy, ... connection between his spine and remaining right pelvis to support ...
... May 4 (HealthDay News) -- U.S. health officials issued ... of liquid over-the-counter drug products that are measured and ... droppers. The U.S. Food and Drug Administration developed ... of overdoses when using liquid over-the-counter (OTC) pain relievers, ...
... , WEDNESDAY, May 4 (HealthDay News) -- A ... group of congenital heart defects that cause a major proportion ... unclear how these cardiac defects -- all malformations of the ... suggests a genetic component may play a role. "It ...
Cached Medicine News:Health News:Families need to know more about feeding tubes for elderly dementia patients 2Health News:Breast cancer multi-gene tests compared 2Health News:Breast cancer multi-gene tests compared 3Health News:Ohio State surgeons rebuild pelvis of cancer patient 2Health News:Ohio State surgeons rebuild pelvis of cancer patient 3Health News:FDA Issues Guidelines for Liquid OTC Medicines 2Health News:New Gene Linked to Congenital Heart Defects 2
Scoville Hemilaminectomy Retractor...
Circular Spine Retractor System for microsurgical interventions in the lumbar and cervical spine region....
... Bone Graft represents an rhBMP-2 (recombinant human ... a bovine-derived absorbable collagen sponge (ACS) carrier. ... device is indicated for spinal fusion procedures ... disease (DDD) at one level from L4-S1, ...
Lorenz 2.0 mm titanium system for the midface provides an excellent alternative to lower profile systems in areas of the midface where greater fixation is needed....
Medicine Products: